Blues’ Early Cost-Effectiveness Study Raises TEC-nical Difficulties – Thoratec
This article was originally published in The Gray Sheet
Executive Summary
BlueCross BlueShield Technology Evaluation Center's April cost-effectiveness analysis of LVAD for destination therapy was premature, Thoratec VP-Reimbursement Robin Bostic asserted June 29